While the interaction between the PTEN, PAFR, and EGFR pathways remains elusive, the consummated findings provide compelling evidence that the PTEN-PAFR and PAFR-EGFR axis (and their downstream cascades) represent novel targets for malignancies, including NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.